Most Read Articles
one year ago
Adjunct boceprevir is  effective for patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-genotype-1 coinfection unresponsive to pegylated interferon/ribavarin (PEGIFN/RBV) therapy, as shown in a retrospective study.
2 years ago
Current management of liver abscess is by intravenous antibiotics and percutaneous treatment. The efficacy of this management was assessed in this study.
Jackey Suen, 2 years ago
Over one-third of patients with prior hepatitis B virus (HBV) exposure had HBV reactivation 2 years after haematopoietic stem cell transplantation (HSCT), according to a study by The University of Hong Kong (HKU). 
2 years ago
A randomised controlled trial demonstrated the safety of low-dose peginterferon α-2b with escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1.

Excerpts from the EXPERT Program Module 3: “Cardiovascular and Fatty Liver Diseases”

one year ago
Sanofi’s approach in providing medical education has evolved over the years, by not only limiting the content to disease management and patient outcomes, but also taking into consideration of the various challenges faced by doctors across the different sectors. 

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
one year ago
Adjunct boceprevir is  effective for patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-genotype-1 coinfection unresponsive to pegylated interferon/ribavarin (PEGIFN/RBV) therapy, as shown in a retrospective study.
2 years ago
Current management of liver abscess is by intravenous antibiotics and percutaneous treatment. The efficacy of this management was assessed in this study.
Jackey Suen, 2 years ago
Over one-third of patients with prior hepatitis B virus (HBV) exposure had HBV reactivation 2 years after haematopoietic stem cell transplantation (HSCT), according to a study by The University of Hong Kong (HKU). 
2 years ago
A randomised controlled trial demonstrated the safety of low-dose peginterferon α-2b with escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1.